CDAK Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (4 Apr 2024 @ 16:00):

Stats
Today's Volume	14.21M
Average Volume	0.00
Market Cap	2.83M
EPS	$0 ( 2023-11-01 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.120
ATR14	$0.0210 (105.00%)

Insider Trading

Date	Person	Action	Amount	type
2023-03-30	Howze Yalonda	Sell	1 628	Common Stock
2023-03-29	Sathyanarayanan Sriram	Sell	11 762	Common Stock
2023-03-28	Konstantinov Konstantin	Sell	7 432	Common Stock
2023-03-28	Konstantinov Konstantin	Sell	1 932	Common Stock
2023-03-28	Bain Linda	Sell	13 412	Common Stock

INSIDER POWER
93.11
Last 100 transactions
Buy: 14 044 661 \| Sell: 316 076

Volume Correlation

Long: -0.25 (neutral)

Short: 0.79 (moderate)

Signal:(35.08) Neutral

Codiak BioSciences, Inc. Correlation

10 Most Positive Correlations
DTEA	0.934
PAYO	0.888
NAII	0.886
MKTX	0.884
NLSP	0.883
PMTS	0.883
OBNK	0.88
PRAA	0.879
THMA	0.877
VEDU	0.876

10 Most Negative Correlations
RMRM	-0.947
CVLT	-0.945
EVLV	-0.941
APYX	-0.937
FLXN	-0.937
CELH	-0.935
APLD	-0.929
PRSR	-0.927
QTRX	-0.926
CNCE	-0.925

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Codiak BioSciences, Inc. Correlation - Currency/Commodity

-0.44
( neutral )

-0.40
( neutral )

0.00
( neutral )

0.82
( strong )

-0.50
( neutral )

0.17
( neutral )

Codiak BioSciences, Inc. Financials

Annual	2021
Revenue:	$22.94M
Gross Profit:	$0.00 (0.00 %)
EPS:	$-1.664

Q3	2022
Revenue:	$28 000.00
Gross Profit:	$28 000.00 (100.00 %)
EPS:	$-0.680

Q2	2022
Revenue:	$13.15M
Gross Profit:	$13.15M (100.00 %)
EPS:	$-0.290

Q1	2022
Revenue:	$12.70M
Gross Profit:	$12.70M (100.00 %)
EPS:	$-0.350

Financial Reports:

No articles found.

Codiak BioSciences, Inc.

Codiak BioSciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing exosome-based therapeutics for the treatment of oncology, neuro-oncology, neurology, neuromuscular diseases, infectious diseases, and other diseases. Its lead product candidates are exoSTING and exoIL-12 exosome therapeutic candidates for the treatment of various solid tumors. The company is also developing exoASO-STAT6, an antisense oligonucleotide targeting the STAT6 transcription factor; and exoVACC, a modular platform for constructing precision vaccines. It has a collaboration agreement with the Jazz Pharmaceuticals Ireland Limited, Sarepta Therapeutics, Inc., Kayla Therapeutics S.A.S., Washington University, Ragon Institute of MGH, MIT, and Harvard. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.